Abclone announced on April 7 that the next-generation antibody-drug conjugate (ADC) technology, which it licensed from the ...
A new wave of antibody-targeted anticancer therapies is showing great clinical promise, with the potential to transform cancer treatment. These antibody-drug conjugates (ADCs) are multicomponent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results